05 May 2022 | News
The expansion support biotech clinical services in the US to assist in later phase global studies.
Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of its expansion program. The expansion support biotech clinical services in the US to assist in later phase global studies.
Novotech CEO Dr. John Moller said "This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. A unified approach to systems and well developed SOPs will deliver the clinical needs across the region"
Nancy C.G. Snowden, founder and CEO of NCGS, said "NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations. Our lean organizational structure and nimble operational model with highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real-time as the needs of the trial evolve".
Novotech serves biotechs globally, leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS, a privately held CRO with biopharma delivery compliments this with a broad US site base and hundreds of investigators with relationships spanning nearly four decades